Remi Droller

Rémi Droller is currently a managing partner of Kurma Partners SA and a member of the board of directors of Dyncaure SAS, ImCheck Therapeutics SAS, Orphazyme A/S, OxThera AB, AM-Pharma BV, Flamingo Therapeutics BV, and Pharvaris BV. He started at CDC Innovation from 2000 to 2003, later joining AGF Private Equity (now Idinvest Partners) where he developed the investment activity in the life sciences and made investments such as Novagali Pharma (listed on Euronext and acquired by Santen) Prosensa Therapeutics (listed on Nasdaq and acquired by Biomarin) Vivacta (acquired by Novartis), IntegraGen (listed on Alternext) Onxeo (listed on Euronext). Rémi Droller holds a master’s degree in molecular biology from Pierre and Marie Curie University in Paris and a Master’s degree in finance and management of innovation from AgroParisTech.